A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2023-03-01 DOI:10.2217/pme-2022-0100

Touraj Mahmoudi, Donya Ghorbani, Gholamreza Rezamand, Niloufar Dehestan, Golnaz Jeddi, Asadollah Asadi, Hossein Nobakht, Reza Dabiri, Hamid Farahani, Seidamir Pasha Tabaeian, Mohammad Reza Zali

{"title":"A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease.","authors":"Touraj Mahmoudi, Donya Ghorbani, Gholamreza Rezamand, Niloufar Dehestan, Golnaz Jeddi, Asadollah Asadi, Hossein Nobakht, Reza Dabiri, Hamid Farahani, Seidamir Pasha Tabaeian, Mohammad Reza Zali","doi":"10.2217/pme-2022-0100","DOIUrl":null,"url":null,"abstract":"Background: Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (NAMPT) and NAFLD. Methods: We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the NAMPT gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case-control genetic association study. Results: The 'CC+TC' genotype of NAMPT rs1319501 in comparison to the 'TT' genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31-0.82). Conclusion: This study showed, for the first time, that the carriers of the NAMPT rs1319501 'CC+TC' genotype had a 45% decreased risk for NAFLD.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0100","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (NAMPT) and NAFLD. Methods: We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the NAMPT gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case-control genetic association study. Results: The 'CC+TC' genotype of NAMPT rs1319501 in comparison to the 'TT' genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31-0.82). Conclusion: This study showed, for the first time, that the carriers of the NAMPT rs1319501 'CC+TC' genotype had a 45% decreased risk for NAFLD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

内脏脂肪素基因启动子多态性(rs1319501)与非酒精性脂肪肝的易感性相关。

背景:考虑到visfatin在非酒精性脂肪性肝病(NAFLD)中的作用，本文探讨了visfatin基因(NAMPT)与NAFLD之间的潜在联系。方法:在本病例-对照遗传关联研究中，我们采用pcr -限制性片段长度多态性方法对154例活检证实的NAFLD患者和158例对照患者的NAMPT基因rs1319501启动子变异进行基因分型。结果:NAMPT rs1319501“CC+TC”基因型在NAFLD患者中的发生率低于“TT”基因型，校正混杂因素后差异仍有统计学意义(p = 0.029;优势比= 0.55;95% ci = 0.31-0.82)。结论:本研究首次表明，携带NAMPT rs1319501“CC+TC”基因型的NAFLD风险降低45%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.